Ifosfamide with mesna uroprotection in the management of lung cancer

P. Y. Holoye, Bonnie S Glisson, J. S. Lee, H. M. Dhingra, W. K. Murphy, T. Umsawasdi, J. K. Levy, D. Jeffries, M. N. Raber, W. K. Hong

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Fourteen patients with extensive disease small cell bronchogenic carcinoma (SCBC) received ifosfamide at 2,000 mg/m2/day for 5 consecutive days with simultaneous mesna and vincristine while 26 patients with extensive disease non-small-cell bronchogenic carcinoma (N-SCBC) received the same regimen without vincristine. Eight partial responses (57%) were observed with a 40-week median survival in the case of SCBC and four partial remissions (15%) with a 31-week median survival in N-SCBC. Granulocytopenia was the dose -limiting toxicity, whereas urotoxicity was well controlled with mesna. Neuropsychiatric toxicity consisted of anxiety, agitation, confusion, and hallucination. Neurobehavioral testing detected worsened performance during ifosfamide treatment. Ifosfamide is one of the few active agents in N-SCBC.

Original languageEnglish (US)
Pages (from-to)148-155
Number of pages8
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number2
StatePublished - Jan 1 1990

Fingerprint

Mesna
Ifosfamide
Bronchogenic Carcinoma
Lung Neoplasms
Small Cell Carcinoma
Vincristine
Confusion
Agranulocytosis
Survival
Hallucinations
Anxiety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Holoye, P. Y., Glisson, B. S., Lee, J. S., Dhingra, H. M., Murphy, W. K., Umsawasdi, T., ... Hong, W. K. (1990). Ifosfamide with mesna uroprotection in the management of lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 13(2), 148-155.

Ifosfamide with mesna uroprotection in the management of lung cancer. / Holoye, P. Y.; Glisson, Bonnie S; Lee, J. S.; Dhingra, H. M.; Murphy, W. K.; Umsawasdi, T.; Levy, J. K.; Jeffries, D.; Raber, M. N.; Hong, W. K.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 2, 01.01.1990, p. 148-155.

Research output: Contribution to journalArticle

Holoye, PY, Glisson, BS, Lee, JS, Dhingra, HM, Murphy, WK, Umsawasdi, T, Levy, JK, Jeffries, D, Raber, MN & Hong, WK 1990, 'Ifosfamide with mesna uroprotection in the management of lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 13, no. 2, pp. 148-155.
Holoye, P. Y. ; Glisson, Bonnie S ; Lee, J. S. ; Dhingra, H. M. ; Murphy, W. K. ; Umsawasdi, T. ; Levy, J. K. ; Jeffries, D. ; Raber, M. N. ; Hong, W. K. / Ifosfamide with mesna uroprotection in the management of lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1990 ; Vol. 13, No. 2. pp. 148-155.
@article{c8337bf900b44b2f8fba62d82c4d9aac,
title = "Ifosfamide with mesna uroprotection in the management of lung cancer",
abstract = "Fourteen patients with extensive disease small cell bronchogenic carcinoma (SCBC) received ifosfamide at 2,000 mg/m2/day for 5 consecutive days with simultaneous mesna and vincristine while 26 patients with extensive disease non-small-cell bronchogenic carcinoma (N-SCBC) received the same regimen without vincristine. Eight partial responses (57{\%}) were observed with a 40-week median survival in the case of SCBC and four partial remissions (15{\%}) with a 31-week median survival in N-SCBC. Granulocytopenia was the dose -limiting toxicity, whereas urotoxicity was well controlled with mesna. Neuropsychiatric toxicity consisted of anxiety, agitation, confusion, and hallucination. Neurobehavioral testing detected worsened performance during ifosfamide treatment. Ifosfamide is one of the few active agents in N-SCBC.",
author = "Holoye, {P. Y.} and Glisson, {Bonnie S} and Lee, {J. S.} and Dhingra, {H. M.} and Murphy, {W. K.} and T. Umsawasdi and Levy, {J. K.} and D. Jeffries and Raber, {M. N.} and Hong, {W. K.}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "13",
pages = "148--155",
journal = "American Journal of Clinical Oncology: Cancer Clin",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Ifosfamide with mesna uroprotection in the management of lung cancer

AU - Holoye, P. Y.

AU - Glisson, Bonnie S

AU - Lee, J. S.

AU - Dhingra, H. M.

AU - Murphy, W. K.

AU - Umsawasdi, T.

AU - Levy, J. K.

AU - Jeffries, D.

AU - Raber, M. N.

AU - Hong, W. K.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Fourteen patients with extensive disease small cell bronchogenic carcinoma (SCBC) received ifosfamide at 2,000 mg/m2/day for 5 consecutive days with simultaneous mesna and vincristine while 26 patients with extensive disease non-small-cell bronchogenic carcinoma (N-SCBC) received the same regimen without vincristine. Eight partial responses (57%) were observed with a 40-week median survival in the case of SCBC and four partial remissions (15%) with a 31-week median survival in N-SCBC. Granulocytopenia was the dose -limiting toxicity, whereas urotoxicity was well controlled with mesna. Neuropsychiatric toxicity consisted of anxiety, agitation, confusion, and hallucination. Neurobehavioral testing detected worsened performance during ifosfamide treatment. Ifosfamide is one of the few active agents in N-SCBC.

AB - Fourteen patients with extensive disease small cell bronchogenic carcinoma (SCBC) received ifosfamide at 2,000 mg/m2/day for 5 consecutive days with simultaneous mesna and vincristine while 26 patients with extensive disease non-small-cell bronchogenic carcinoma (N-SCBC) received the same regimen without vincristine. Eight partial responses (57%) were observed with a 40-week median survival in the case of SCBC and four partial remissions (15%) with a 31-week median survival in N-SCBC. Granulocytopenia was the dose -limiting toxicity, whereas urotoxicity was well controlled with mesna. Neuropsychiatric toxicity consisted of anxiety, agitation, confusion, and hallucination. Neurobehavioral testing detected worsened performance during ifosfamide treatment. Ifosfamide is one of the few active agents in N-SCBC.

UR - http://www.scopus.com/inward/record.url?scp=0025301720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025301720&partnerID=8YFLogxK

M3 - Article

C2 - 2156418

AN - SCOPUS:0025301720

VL - 13

SP - 148

EP - 155

JO - American Journal of Clinical Oncology: Cancer Clin

JF - American Journal of Clinical Oncology: Cancer Clin

SN - 0277-3732

IS - 2

ER -